openPR Logo
Press release

Cancer Anorexia Market Expected to Reach USD 3.5 Billion by 2034

09-05-2025 01:27 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Cancer Anorexia Market

Cancer Anorexia Market

Cancer anorexia, often linked with cancer cachexia, is a debilitating condition characterized by loss of appetite, reduced food intake, and progressive weight loss in cancer patients. It is one of the most common and distressing cancer-related complications, affecting up to 80% of patients with advanced cancer. Beyond worsening quality of life, cancer anorexia contributes to poor treatment tolerance, faster disease progression, and higher mortality rates.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71597

Managing cancer anorexia requires a multidisciplinary approach, including nutritional support, appetite stimulants, metabolic modulators, and psychological interventions. In recent years, pharmaceutical companies and research institutes have intensified efforts to develop novel drugs targeting the underlying metabolic and inflammatory pathways. With rising cancer prevalence worldwide, the global Cancer Anorexia Market is projected to expand steadily through 2034.

Market Overview
• Market Size 2024: USD 1.9 billion
• Forecast 2034: USD 3.5 billion
• CAGR (2024-2034): 6.3%

Growth is being driven by rising cancer incidence, better recognition of cachexia-anorexia syndromes, and expansion of supportive oncology care globally.

Key Growth Drivers
• Increasing prevalence of advanced cancers requiring supportive care.
• Rising awareness of cachexia management guidelines.
• Development of novel appetite stimulants and metabolic modulators.
• Growing integration of nutritional interventions in oncology care.
• Expanding palliative care services worldwide.

Key Challenges
• Lack of standardized global treatment guidelines.
• Limited efficacy of existing appetite stimulants (e.g., megestrol acetate).
• High unmet need for targeted therapies addressing metabolic pathways.
• Underdiagnosis and undertreatment in low-resource settings.

Leading Players
Prominent companies include Pfizer Inc., Novartis AG, Merck & Co., Bristol Myers Squibb, Teva Pharmaceuticals, Fresenius Kabi, Nestlé Health Science, Mylan N.V., Hikma Pharmaceuticals, and Kyowa Kirin Co., Ltd.

Segmentation Analysis
The Cancer Anorexia Market can be segmented as follows:

• By Therapy Type
o Pharmacological Interventions
 Appetite Stimulants (Megestrol Acetate, Corticosteroids)
 Metabolic Modulators (Anti-inflammatory Agents, Ghrelin Mimetics)
o Nutritional Support & Supplements
o Psychological & Behavioral Interventions
o Multimodal Approaches

• By Cancer Type
o Lung Cancer
o Gastrointestinal Cancers
o Pancreatic Cancer
o Head & Neck Cancer
o Others (Breast, Hematologic Malignancies)

• By End Use
o Hospitals & Oncology Centers
o Specialty Clinics
o Palliative & Hospice Care Facilities
o Research & Academic Institutes

Segmentation Summary: While pharmacological interventions dominate current use, the fastest growth is in multimodal care approaches, combining drug therapy, nutritional interventions, and psychological support.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71597/cancer-anorexia-market

Regional Analysis
• North America
Largest market, driven by strong oncology infrastructure, high prevalence of advanced cancer cases, and FDA-backed appetite stimulant approvals. The U.S. leads in adoption of multimodal cachexia management.
• Europe
Significant presence supported by EMA approvals, robust palliative care frameworks, and national cancer care guidelines. Germany, France, and the UK are key contributors.
• Asia-Pacific (APAC)
Expected to record the fastest CAGR through 2034, supported by rising cancer burden, improving healthcare access, and growing demand for palliative care in China, Japan, and India.
• Middle East & Africa
Moderate growth, with GCC countries expanding oncology and palliative care services, while broader Africa faces infrastructure challenges.
• Latin America
Brazil and Mexico dominate, though affordability of novel drugs remains a barrier in several markets.
Regional Summary: North America and Europe dominate today's market, while APAC is projected to grow fastest, reflecting the region's rising cancer prevalence and increasing investment in supportive oncology services.

Market Dynamics
Growth Drivers
• Expansion of real-world evidence (RWE) programs for supportive oncology.
• Increasing pharma investment in ghrelin mimetics and based therapies.
• Strong advocacy for integrating cachexia care into cancer treatment guidelines.
• Growth of telehealth and digital nutrition monitoring platforms.

Challenges
• Limited drug development success due to complex cachexia biology.
• Variability in patient response to appetite stimulants.
• Low physician awareness in emerging markets.
• Lack of reimbursement for supportive care therapies in some regions.

Emerging Trends
• Development of ghrelin receptor agonists and myostatin inhibitors.
• Integration of AI-driven nutrition monitoring and predictive analytics.
• Increasing adoption of personalized nutrition and precision supportive care.
• Expansion of based drug research.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71597

Competitor Analysis
Major Players
• Pfizer Inc.
• Novartis AG
• Merck & Co.
• Bristol Myers Squibb
• Teva Pharmaceuticals
• Fresenius Kabi
• Nestlé Health Science
• Mylan N.V.
• Hikma Pharmaceuticals
• Kyowa Kirin Co., Ltd.

Competitive Landscape
The market is moderately fragmented, with Pfizer, Novartis, and Merck leading pharmacological interventions, while Nestlé Health Science and Fresenius Kabi dominate nutritional solutions. Companies are pursuing strategies including orphan drug designations, partnerships with palliative care networks, and R&D in ghrelin-based drugs.

Conclusion
The Cancer Anorexia Market is projected to grow from USD 1.9 billion in 2024 to USD 3.5 billion by 2034, at a CAGR of 6.3%. Rising global cancer prevalence, innovation in pharmacological and nutritional interventions, and greater focus on palliative care will fuel market expansion.

Key Takeaways:
• Market to reach USD 3.5 billion by 2034, at 6.3% CAGR.
• Pharmacological interventions dominate, but multimodal supportive care is expanding rapidly.
• North America and Europe lead, while APAC is the fastest-growing region.
• Competitive dynamics shaped by pharma innovation, nutrition leaders, and rare disease research collaborations.

The next decade will mark a transformative phase in supportive oncology, as novel drugs, precision nutrition, and integrated care models improve outcomes for patients with cancer anorexia worldwide.

This report is also available in the following languages : Japanese (がん拒食症市場), Korean (암 식욕 부진 시장), Chinese (癌症厌食症市场), French (Marché de l'anorexie cancéreuse), German (Markt für Krebs-Magersucht), and Italian (Mercato dell'anoressia e del cancro), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71597/cancer-anorexia-market#request-a-sample

Our More Reports:

Lipodystrophy Market
https://exactitudeconsultancy.com/reports/71998/lipodystrophy-market

Metabolic Acidosis Market
https://exactitudeconsultancy.com/reports/71999/metabolic-acidosis-market

Nephrotic Syndrome Market
https://exactitudeconsultancy.com/reports/72000/nephrotic-syndrome-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Anorexia Market Expected to Reach USD 3.5 Billion by 2034 here

News-ID: 4171839 • Views:

More Releases from Exactitude Consultancy

Vulvar Cancer Market is expected to nearly double by 2034, reaching USD 850 million
Vulvar Cancer Market is expected to nearly double by 2034, reaching USD 850 mill …
Vulvar cancer is a rare gynecologic malignancy that arises on the external female genitalia, most commonly as squamous cell carcinoma, though melanoma, adenocarcinoma, and sarcoma subtypes also occur. While it accounts for only 4-5% of all gynecologic cancers, vulvar cancer is associated with significant morbidity, especially when diagnosed late. Risk factors include human papillomavirus (HPV) infection, lichen sclerosus, smoking, and advancing age. Download Full PDF Sample Copy of Market Report @
Upper Tract Urothelial Cancer Market Set to Witness Significant Growth by 2025-2034
Upper Tract Urothelial Cancer Market Set to Witness Significant Growth by 2025-2 …
Introduction Upper tract urothelial cancer (UTUC) is a rare and aggressive malignancy that originates in the lining of the renal pelvis and ureters. Accounting for only 5-10% of urothelial carcinomas, UTUC is often diagnosed late due to its asymptomatic progression, leading to poor outcomes in advanced stages. Traditionally treated with nephroureterectomy, chemotherapy, and radiotherapy, UTUC management has evolved significantly in recent years with the arrival of immune checkpoint inhibitors, FGFR inhibitors, and
Acute Lymphoblastic Leukemia Market to Double by 2034, Reaching USD 7.5 Billion
Acute Lymphoblastic Leukemia Market to Double by 2034, Reaching USD 7.5 Billion
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow, characterized by the overproduction of immature lymphocytes. It is the most common cancer in children but also occurs in adults, often with poorer outcomes. While survival rates in pediatric ALL have improved dramatically, adult and relapsed/refractory cases remain challenging, highlighting the urgent need for innovative treatments. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71595 The treatment
TRK Fusion Cancer Market Set to Witness Significant Growth by 2025-2034
TRK Fusion Cancer Market Set to Witness Significant Growth by 2025-2034
TRK Fusion Cancer Market Outlook 2024-2034: Targeted Therapies and Precision Medicine Transform Rare Oncology Care Introduction TRK fusion cancer is a rare form of cancer caused by neurotrophic tyrosine receptor kinase (NTRK) gene fusions, which can occur across multiple tumor types including sarcomas, thyroid cancer, lung cancer, and gastrointestinal tumors. These fusions drive uncontrolled tumor growth, making them a critical target for precision medicine. Over the past few years, TRK fusion cancer has

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose. Increase in incidence of target diseases like cancer is key driving factor which is expected to boost
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports. Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For